Core Viewpoint - The article highlights three dividend-paying stocks—AbbVie, Home Depot, and ExxonMobil—that have consistently raised their dividends for over a decade, offering yields significantly higher than the S&P 500 average, making them attractive long-term investments. AbbVie - AbbVie currently offers a dividend yield of approximately 2.9%, which is more than double the S&P 500 average of 1.2% [3] - The company has a history of over 50 consecutive years of dividend increases, qualifying it as a Dividend King [3][4] - AbbVie recently raised its dividend by 5.5%, and since its spin-off from Abbott Laboratories, it has increased quarterly dividends by over 330% [4] - For the first nine months of the year, AbbVie reported an 8% increase in sales, totaling $44.5 billion, with Skyrizi and Rinvoq generating $18.5 billion, surpassing Humira's current quarterly sales of $3.3 billion [6][7] Home Depot - Home Depot has raised its dividend for 16 consecutive years, with a more than 50% increase since 2020, currently yielding 2.7% [8] - Despite facing challenges due to decreased discretionary spending, the company anticipates a 3% sales growth for the current fiscal year [9] - Home Depot's shares have declined by 13% this year, but the company is expected to recover in the long term due to its strong position in the home repair market [12] ExxonMobil - ExxonMobil offers the highest yield among the three at 3.5%, with a history of 43 consecutive years of annual dividend growth at an average rate of 5.8% [13][14] - The company has faced earnings volatility, with a decline of $3.7 billion to $22.3 billion this year, but it maintains strong financial health, with earnings per share of $5.16 exceeding its annual dividend payout of $4.12 [14][16] - ExxonMobil's stock has increased by 8% this year and is trading at an estimated 16 times its future earnings, presenting a good value for income investors [16]

Core Insights - The article discusses the author's background in analytics and accounting, highlighting over 10 years of experience in the investment sector, progressing from an analyst to a management role [1]. Group 1 - The author holds a master's degree in Analytics from Northwestern University and a bachelor's degree in Accounting [1]. - The author has a personal interest in dividend investing and aims to share insights with the Seeking Alpha community [1]. Group 2 - The author has disclosed a beneficial long position in several companies, including ABBV, ADP, CTAS, FDS, HRL, JNJ, LOW, NEE, O, PEP, TROW, and WST, through various financial instruments [2]. - The article expresses the author's personal opinions and does not involve compensation from any mentioned companies [2].

Core Insights - The article highlights the attractiveness of certain exchange-traded funds (ETFs) that offer yields significantly higher than the S&P 500 average, which is currently at 1.2% [2][4]. Group 1: Vanguard International High Dividend Yield ETF - The Vanguard International High Dividend Yield ETF provides a yield of approximately 4%, which is more than three times the S&P 500 average [4]. - This ETF has a low expense ratio of 0.17% and focuses on international markets, with 43% of its holdings in European stocks, 26% in the Pacific region, and 22% in emerging markets [5]. - The ETF contains over 1,500 stocks, with no single stock exceeding 2% of the total portfolio, which mitigates risk associated with individual stock performance [6]. Group 2: Schwab U.S. Dividend Equity ETF - The Schwab U.S. Dividend Equity ETF focuses on U.S. dividend stocks and has around 100 stocks in its portfolio, suggesting a more selective investment approach [9][10]. - This ETF yields 3.8% and has a very low expense ratio of 0.06%, with a beta of 0.79 indicating lower volatility compared to the Vanguard fund [13]. - Despite a 1% decline this year, the Schwab ETF has generated approximately 30% returns over five years, excluding dividends, making it a solid long-term investment option [14].

Core Insights - AbbVie has announced two positive updates for Canadians living with ulcerative colitis (UC) [1] - Canada's Drug Agency (CDA-AMC) has recommended SKYRIZI (risankizumab) for reimbursement under specific conditions for adults with moderately to severely active UC [2][3] - AbbVie has completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding SKYRIZI for UC, resulting in a signed Letter of Intent (LOI) [3][5] Summary by Sections Treatment Recommendations - The CDA-AMC's recommendation for SKYRIZI is based on feedback from 25 Canadian clinicians and two patient organizations, ensuring patient perspectives were included [3] - SKYRIZI is indicated for adults with UC who have had inadequate responses to conventional therapies, biologic treatments, or Janus kinase (JAK) inhibitors [8] Clinical Evidence - The positive recommendations for SKYRIZI were supported by evidence from pivotal phase 3 clinical trials, including MOTIVATE, ADVANCE, FORTIFY (for Crohn's disease), and INSPIRE, COMMAND (for UC) [5] Patient Impact - The introduction of SKYRIZI is seen as a significant step towards providing effective treatment options for UC patients, which can help improve their quality of life and long-term health outcomes [5][6] - Approximately 120,000 Canadians are estimated to live with UC, highlighting the need for effective treatment options [7] Company Commitment - AbbVie expresses commitment to improving patient access to innovative medicines for inflammatory bowel disease through collaboration with health authorities [6]

Core Viewpoint - The article highlights eight dividend stocks that cater to various investment styles, emphasizing the importance of balancing current income with long-term growth in a diversified dividend strategy [1][2]. Group 1: Stock Summaries - **American Express (AXP)**: Operates a closed-loop payments network with a yield of 0.87% and a payout ratio of 16%, indicating significant potential for dividend growth due to its affluent customer base and strong pricing power [3][4]. - **JPMorgan Chase (JPM)**: The largest U.S. bank by assets, offering a 2% yield and a 28% payout ratio, making it a solid choice for investors seeking both income and capital appreciation [5]. - **Costco (COST)**: Generates profit primarily from membership fees, with a low yield of 0.5% but a 27% payout ratio and a history of substantial special dividends, showcasing its commitment to shareholder returns [6][7]. - **S&P Global (SPGI)**: Provides essential financial market services with a yield of 0.8% and a 28% payout ratio, boasting a 52-year history of dividend increases, reflecting its strong market position [9]. - **AbbVie (ABBV)**: A biopharmaceutical company with a 3% yield and a remarkable 53 consecutive years of dividend increases, supported by a robust pipeline and strategic acquisitions [10]. - **Pfizer (PFE)**: A major pharmaceutical company with a high yield of 6.7% but a payout ratio near 98%, appealing to income-focused investors despite earnings volatility risks [11]. - **Philip Morris International (PM)**: Offers a 3.8% yield with a payout ratio of nearly 78%, focusing on smoke-free products to differentiate itself and provide growth opportunities [12][13]. - **Nvidia (NVDA)**: A technology company with a minimal yield of 0.02% but a low payout ratio of 1%, indicating strong potential for future dividend growth driven by substantial free cash flow [15].

Core Insights - Pfizer and AbbVie are both leading U.S. pharmaceutical companies with strong positions in various therapeutic areas, with Pfizer's oncology sales accounting for approximately 28% of its total revenues and AbbVie’s immunology drugs contributing around 50% of its net revenues [1][2]. Pfizer (PFE) Overview - Pfizer has strengthened its oncology position with the acquisition of Seagen in 2023, leading to a 7% increase in oncology revenues year-to-date, driven by key drugs [4]. - Non-COVID operational revenues are improving, with a 9% operational increase in recently launched and acquired products in the first nine months of 2025, supporting growth expectations for 2026 [5]. - Pfizer anticipates cost savings of $7.7 billion by the end of 2027 through restructuring and cost reduction efforts, with a dividend yield of around 7% [6]. - The company is expanding its pipeline through acquisitions, including a $10 billion deal for Metsera, which adds significant potential in the obesity market [7]. - Pfizer faces challenges with declining sales of COVID products and expects a significant impact from patent expirations between 2026-2030, estimating a $1 billion unfavorable impact from the Inflation Reduction Act [8][10]. AbbVie (ABBV) Overview - AbbVie has successfully navigated the loss of exclusivity for Humira by launching new immunology drugs, Skyrizi and Rinvoq, which generated combined sales of $18.5 billion in the first nine months of 2025 [11][12]. - The oncology segment contributed $5.0 billion in revenues, while neuroscience drugs saw a 20.3% increase in sales, totaling almost $7.8 billion [13]. - AbbVie has pursued inorganic growth through over 30 M&A transactions since early 2024, particularly in immunology, while facing near-term challenges from Humira's biosimilars and competitive pressures [14]. - The aesthetics portfolio has seen a 7.4% decline in global sales, impacted by macroeconomic challenges and low consumer sentiment [15]. Financial Estimates and Performance - The Zacks Consensus Estimate for Pfizer's 2025 sales implies a 1.1% decrease, while AbbVie's estimates indicate an 8.1% increase in sales [16]. - Year-to-date, Pfizer's stock has declined by 3.0%, whereas AbbVie's stock has risen by 30.5%, outperforming the industry average of 15.9% [20]. - AbbVie’s dividend yield is 2.8%, compared to Pfizer’s 6.7% [26]. Investment Outlook - Both companies hold a Zacks Rank 3 (Hold), but AbbVie is favored due to its robust growth prospects and lack of significant upcoming loss of exclusivity events [28]. - AbbVie expects to achieve mid-single-digit revenue growth in 2025, driven by the strong performance of Skyrizi and Rinvoq, with a high single-digit CAGR projected through 2029 [29].

Core Insights - CollPlant Biotechnologies reported financial results for Q3 2025, showing significant growth in revenue and advancements in its product development pipeline [1][15][24]. Financial Performance - GAAP revenues for Q3 2025 were $77,000, up from $4,000 in Q3 2024, primarily due to increased sales of rhCollagen-based products [15]. - For the nine months ended September 30, 2025, GAAP revenues reached $2.3 million compared to $351,000 for the same period in 2024 [16]. - The company reported a GAAP net loss of $3.5 million for Q3 2025, an improvement from a net loss of $4.3 million in Q3 2024 [24]. Product Development and Innovation - CollPlant is advancing its dermal filler program and has achieved a key milestone in collaboration with AbbVie, receiving a $2 million payment [3][17]. - The company’s rhCollagen-based bioink, Collink.3D™, has shown superior performance compared to Matrigel® in supporting structured tissue formation, indicating a potential market opportunity of approximately $100 million with an annual growth rate of over 10% [2][15]. - A fully humanized bioprinted skin model developed at Mayo Clinic using rhCollagen offers an ethical alternative to animal testing, broadening the application of CollPlant's technology in medical and pharmaceutical research [2][16]. Strategic Initiatives - CollPlant has initiated a cost reduction plan, including a workforce reduction of approximately 25%, to extend its cash runway [5][21]. - The company is expanding its distribution capabilities in North America through a new logistics partnership, enhancing support for its rhCollagen and BioInk product lines [7][12]. - Plans are in place to actively seek a strategic partner for the continued development of its novel regenerative breast implant product candidate [6]. Market Expansion - CollPlant has expanded its international distribution network for its tendon-repair product, Vergenix™ STR, entering seven new markets in 2025, with plans for further expansion in Europe and Asia in 2026 [13][14]. - The company appointed Bowman Bagley as Vice President, Commercial North America, to lead its commercial strategy and execution across the region [16]. Balance Sheet and Cash Flow - As of September 30, 2025, cash and cash equivalents were $8.5 million, with cash used in operating activities amounting to $6.5 million for the nine months ended September 30, 2025 [26]. - The company reported a decrease in cash used in investing activities to $12,000 from $481,000 in the same period of 2024, primarily due to reduced purchases of property and equipment [27].

Core Points - AbbVie, in collaboration with adMare BioInnovations, has launched the AbbVie Biotech Innovators Award to support innovation in Quebec's life sciences sector [1][2] - The award aims to assist early-stage biotechnology startups that align with AbbVie's therapeutic focus areas, including immunology, oncology, neuroscience, eye care, and aesthetics [2][3] - The selected startup will receive a year of laboratory and office space at the adMare Innovation Centre in Montreal, along with access to AbbVie's expertise and mentorship [3][9] Industry Impact - Quebec's life sciences and health technologies industry contributes $6.5 billion to the province's GDP, highlighting its significance in the regional economy [5] - adMare BioInnovations has a strong track record, having built 38 companies that have attracted $2.5 billion in risk capital and created around 1,000 jobs in Canada [8] - The initiative reflects a commitment to fostering a thriving biotech ecosystem in Quebec, aiming to accelerate the development of transformative therapies [4][9]

Core Insights - REGENXBIO Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference with a fireside chat scheduled for December 2, 2025, at 8:30 a.m. ET [1] - The company is focused on advancing gene therapy, particularly in treating rare and retinal diseases, with a late-stage pipeline that includes several investigational therapies [2] Company Overview - REGENXBIO, founded in 2009, specializes in AAV gene therapy and aims to improve lives through its curative potential [2] - The company has developed treatments such as RGX-202 for Duchenne muscular dystrophy, RGX-121 for MPS II, and RGX-111 for MPS I, in collaboration with Nippon Shinyaku [2] - REGENXBIO is also working with AbbVie on surabgene lomparvovec (ABBV-RGX-314) for wet AMD and diabetic retinopathy [2] - Thousands of patients have been treated using REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA® [2] Recent Developments - The company announced the completion of pivotal enrollment in the AFFINITY DUCHENNE® trial for RGX-202, marking a significant milestone in its Duchenne gene therapy program [5]

Accessibility StatementSkip Navigation AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma NORTH CHICAGO, Ill., Nov. 24, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025. Management will participate in a fireside chat at 7:30 a.m. Central time. A live audio webcast of the presentation will be accessible thro ...